Loading…
LeonaBio, Inc. is projected to rise to $13.66 by 2027, a +42% move from its current price of $9.60. LONA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $9.25 | $9.61 | $9.98 | +0.09% |
| Jul 15 | $9.12 | $9.62 | $10.15 | +0.18% |
| Jul 16 | $9.02 | $9.63 | $10.28 | +0.27% |
| Jul 17 | $8.93 | $9.63 | $10.39 | +0.36% |
| Jul 18 | $8.86 | $9.64 | $10.49 | +0.45% |
| Jul 19 | $8.80 | $9.65 | $10.59 | +0.54% |
| Jul 20 | $8.74 | $9.66 | $10.68 | +0.63% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $8.74 | $9.66 | $10.68 | +0.63% |
| Week 2 | $8.44 | $9.72 | $11.20 | +1.26% |
| Week 3 | $8.22 | $9.78 | $11.63 | +1.89% |
| Week 4 | $8.06 | $9.84 | $12.02 | +2.53% |
| Week 5 | $7.92 | $9.90 | $12.39 | +3.17% |
| Week 6 | $7.80 | $9.97 | $12.74 | +3.82% |
| Week 7 | $7.70 | $10.03 | $13.07 | +4.47% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
LeonaBio, Inc. is a healthcare company in the clinical-stage biopharmaceutical field that develops novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. Its lead products include lasofoxifene and ATH-1105, a novel small molecule therapy with the potential to address devastating diseases where current treatment options are limited or ineffective.
The company’s product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of diabetic neuropathy, which is in phase 1 clinical trial; and ATH-1017 for the treatment of Alzheimer's disease and Parkinson's disease, which is in phase 2 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as Athira Pharma, Inc. and changed its name to LeonaBio, Inc.
in January 2026. LeonaBio, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
LeonaBio, Inc. (LONA) is a healthcare stock currently trading at $9.39 per share, with a market capitalization of $88.21M and a market rank of 4299.
The long-range forecast for LeonaBio shows a bullish trajectory with the 2026 average price at $9.39 and a path higher to 2050, where the average is projected at $143.66. The implied ROIs climb from 0 in 2026 to 42.7 in 2027, rising further to 54 in 2028, 83.5 in 2029, 94.3 in 2030, 107.3 in 2031, 197.7 in 2032, 269.9 in 2033, 306.8 in 2034, 352.7 in 2035, 734.5 in 2040, and 1429.9 in 2050.
These figures reflect bullish sentiment across the forecast horizon, with the highest upside appearing toward the end of the period.
A major floor 44.8% below — a decisive break under it would weaken the trend.
The nearest floor, 17.9% below — buyers have tended to step in here.
Price is pressing into resistance (0.4% away) — a breakout level to watch.
A major ceiling 21.7% above — clearing it would confirm fresh momentum.
Key LONA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LONA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $9.02 | Buy | $9.16 | Buy |
| MA 10 | $8.98 | Buy | $8.98 | Buy |
| MA 20 | $8.66 | Buy | $8.88 | Buy |
| MA 50 | $9.19 | Buy | $8.89 | Buy |
| MA 100 | $8.66 | Buy | $8.39 | Buy |
| MA 200 | $6.77 | Buy | $7.51 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 58.70 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 180.54 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.12 | Buy |
| ROC (12) | 14.97 | Buy |
| Bollinger %B (20,2) | 1.03 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.17 | Sell |
| Awesome (5,34) | 0.15 | Buy |
| Ultimate (7,14,28) | 59.02 | Neutral |
| Momentum (10) | 0.91 | Buy |
| Aroon Osc (25) | 64.00 | Buy |
| Hull MA (9) | 9.22 | Buy |
| ADX (14) | 11.45 | Neutral |
| ATR (14) | 0.31 | Info |
The 30-day technical picture is bullish in tone. RSI (14) is at 60, signaling ongoing positive momentum without being overbought. The stock price sits above both key moving averages: the SMA50 at $9.17 and the SMA200 at $6.74, which is consistent with an upward bias in the near term.
Support is marked at $7.88 and resistance at $9.81. The 30-day price range spans from a low of $7.27 to a high of $12.12, indicating a broad swing but with a current tilt toward upside given the bullish sentiment and technical setup.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.34 | $9.60 | $13.42 | 0% | Neutral | |
| $10.48 | $13.66 | $19.04 | +42% | Bullish | |
| $10.92 | $14.81 | $21.67 | +54% | Bullish | |
| $12.54 | $17.60 | $26.73 | +83% | Bullish | |
| $12.95 | $18.72 | $29.35 | +95% | Bullish | |
| $13.49 | $20.06 | $32.31 | +109% | Bullish | |
| $18.66 | $28.47 | $46.99 | +197% | Bullish | |
| $22.69 | $35.49 | $59.86 | +270% | Bullish | |
| $24.44 | $39.13 | $67.35 | +308% | Bullish | |
| $26.41 | $43.26 | $75.84 | +351% | Bullish | |
| $43.93 | $79.99 | $151.46 | +733% | Bullish | |
| $66.52 | $146.92 | $310.55 | +14.3x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $4.34 | $9.60 | $11.62 | +0.00% |
| August 2026 | $8.26 | $9.85 | $12.13 | +2.60% |
| September 2026 | $8.65 | $10.41 | $13.02 | +5.73% |
| October 2026 | $8.68 | $10.54 | $13.35 | +1.24% |
| November 2026 | $8.35 | $10.22 | $13.08 | -3.07% |
| December 2026 | $8.43 | $10.38 | $13.42 | +1.59% |
Click any year to see its month-by-month LONA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, LONA is projected to trade between $4.34 and $13.42, averaging $9.60 — a potential gain of 0% from today's $9.60. A consolidation phase looks the most probable path here.
LeonaBio, Inc.'s 2027 outlook centres on $13.66, within a $10.48 to $19.04 range. That is up +42% on the projected 2026 average. That marks a +42% change versus current levels. Momentum favours further upside here.
By 2028, LONA could reach as high as $21.67, with a base case around $14.81 and support toward $10.92 — roughly +54% from $9.60. Buyers look set to stay in control over this stretch.
Expect LONA to range from $12.54 to $26.73 through 2029. The $17.60 average target implies a +83% move from current prices. That is up +19% on the projected 2028 average. Momentum favours further upside here.
The LONA price prediction for 2030 points to an average of $18.72 (low $12.95, high $29.35) — a potential gain of +95% on today's $9.60. Buyers look set to stay in control over this stretch.
In 2031, LONA is projected to trade between $13.49 and $32.31, averaging $20.06 — a potential gain of +109% from today's $9.60. That is up +7% on the projected 2030 average. Momentum favours further upside here.
LeonaBio, Inc.'s 2032 outlook centres on $28.47, within a $18.66 to $46.99 range. That is up +42% on the projected 2031 average. That marks a +197% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, LONA could reach as high as $59.86, with a base case around $35.49 and support toward $22.69 — roughly +270% from $9.60. Momentum favours further upside here.
Expect LONA to range from $24.44 to $67.35 through 2034. The $39.13 average target implies a +308% move from current prices. That is up +10% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The LONA price prediction for 2035 points to an average of $43.26 (low $26.41, high $75.84) — a potential gain of +351% on today's $9.60. Momentum favours further upside here.
In 2040, LONA is projected to trade between $43.93 and $151.46, averaging $79.99 — a potential gain of +733% from today's $9.60. That is up +85% on the projected 2035 average. Buyers look set to stay in control over this stretch.
LeonaBio, Inc.'s 2050 outlook centres on $146.92, within a $66.52 to $310.55 range. That is up +84% on the projected 2040 average. That marks a +14.3x change versus current levels. Momentum favours further upside here.
Investing $1,000 in LONA today (≈ 104.166667 LONA) could be worth
$15,304.58
+$14,304.58 (+1430%) by 2050 · US Dollar
Based on the average projected LONA price of $146.92 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LONAwould be worth at today's price.
$1,000 invested in LONA on Jul 10, 2025 (≈ 237.529689 LONA) would be worth
$2,280.29
+$1,280.29 (+128.0%) today · 2.28× · US Dollar
Based on a LONA entry price of $4.21 vs. today's $9.6.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $8.87 | $1,082.3 | +8.2% |
| 1 month ago | $8.43 | $1,138.79 | +13.9% |
| 3 months ago | $9.69 | $990.71 | -0.9% |
| 6 months ago | $6.55 | $1,465.65 | +46.6% |
| 1 year ago | $4.21 | $2,280.29 | +128.0% |
| All time (5.0y) ago | $100.1 | $95.9 | -90.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LONA forecast.
Our base-case forecast reaches $19.00 around 2031.
Implied market cap at $19.00: $178.48M
Over the multi-year horizon, the forecast paints a clear uptrend for LeonaBio, with the average price rising from $9.39 in 2026 to $143.66 by 2050. The projected ROIs climb from 0 in 2026 to 42.7 in 2027, 54 in 2028, 83.5 in 2029, 94.3 in 2030, 107.3 in 2031, 197.7 in 2032, 269.9 in 2033, 306.8 in 2034, 352.7 in 2035, 734.5 in 2040, and 1429.9 in 2050, with sentiment remaining bullish across the period.
The near- to mid-term drivers include ATH-1105 for ALS in phase 1, ATH-1020 for diabetic neuropathy in phase 1, and ATH-1017 for Alzheimer's and Parkinson's in phase 2, complemented by early preclinical compounds. These pipeline elements suggest potential positive catalysts for scale and value realization, though outcomes of clinical trials are uncertain and not guaranteed.
Investors should consider the inherent uncertainty in clinical-stage programs, regulatory timelines, and trial results when evaluating the forecast path and its long-term implications.
Tap a question to reveal the answer.
2030 avg price is $18.24, with a min of $12.54 and a max of $28.78; ROI is 94.3.
The forecast shows a bullish, long-term path with rising average prices and ROIs (e.g., 42.7 in 2027, 54 in 2028, up to 1429.9 by 2050). It also notes a neutral 2026 starting point (avg $9.39; ROI 0) and the usual uncertainty around clinical-stage outcomes.
Yes. The forecast includes max prices above $50 in multiple years, with 2033 max at $59.04 and 2035 max at $75.15, indicating potential to exceed $50 in the outlook.
The 2026 forecast shows min $4.34, avg $9.39, max $13.20, with ROI 0 and sentiment Neutral.
The 2050 forecast shows min $64.65, avg $143.66, max $306.95, with ROI 1429.9 and sentiment Bullish.
LeonaBio, Inc. Community Discussion
0Share your LeonaBio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.